scholarly journals Microalgal protein AstaP is a potent carotenoid solubilizer and delivery module with a broad carotenoid binding repertoire

FEBS Journal ◽  
2021 ◽  
Author(s):  
Yury B. Slonimskiy ◽  
Nikita A. Egorkin ◽  
Thomas Friedrich ◽  
Eugene G. Maksimov ◽  
Nikolai N. Sluchanko
Keyword(s):  
Delivery Module

Characterization of the Carboxylate Delivery Module of Transcarboxylase:  Following Spontaneous Decarboxylation of the 1.3S-CO2-Subunit by NMR and FTIR Spectroscopies†

Biochemistry ◽  
2002 ◽  
Vol 41 (7) ◽  
pp. 2191-2197 ◽  
Author(s):  
Rosa E. Rivera-Hainaj ◽  
Marianne Pusztai-Carey ◽  
D. Venkat Reddy ◽  
Kiattawee Choowongkomon ◽  
Frank D. Sönnichsen ◽  
...  
Keyword(s):  
Delivery Module

scholarly journals Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module

2017 ◽  
Vol 3 (3) ◽  
pp. e1601314 ◽  
Author(s):  
Hyunjae Lee ◽  
Changyeong Song ◽  
Yong Seok Hong ◽  
Min Sung Kim ◽  
Hye Rim Cho ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Transdermal Drug Delivery ◽  
Glucose Monitoring ◽  
Monitoring Device ◽  
Delivery Module

Effects of continuous administration of oxytocin by an Accurel device on parturition in the rat and on development and diuresis in the offspring

1984 ◽  
Vol 101 (2) ◽  
pp. 121-129 ◽  
Author(s):  
G. J. Boer ◽  
J. Kruisbrink
Keyword(s):  
Controlled Delivery ◽  
Partial Recovery ◽  
Postnatal Exposure ◽  
Water Metabolism ◽  
Continuous Administration ◽  
Body Development ◽  
Oxytocin Receptors ◽  
Delivery Module

ABSTRACT A controlled-delivery module based on microporous Accurel polypropylene tubing, implanted subcutaneously in the rat, was used to release oxytocin for at least 40 days both in vitro and in vivo. Using a dosage rate of approximately 650 ng oxytocin per day and implanting the device in rats on day 17 of pregnancy, the known physiological action of oxytocin in advancing labour was confirmed. The increased concentrations of oxytocin in the mothers gave rise to adverse effects; the course of labour was protracted during expulsions of the first pups and the birth weight was reduced. Postnatally, body development of the pups was also affected, although there was partial recovery when the pups started to feed independently. Both pre- and postnatal exposure of pups to an oxytocin-treated mother reduced their body water turnover measured at 1 month of age. The effects on the course of parturition and during lactation might be explained by a blockade of uterine and mammary gland oxytocin receptors respectively, thereby inhibiting a proper response to pulsatile endogenous oxytocin secretion. The changes in water metabolism, which are opposite to those described for the heterologous hormone vasopressin, are less easy to explain since maternal oxytocin is not supposed to pass the placenta. The results may indicate that clinical use of oxytocin for induction of labour and lactation may have hitherto unrecognized side-effects. J. Endocr. (1984) 101, 121–129

Liposome-based drug delivery of various anticancer agents of synthetic and natural product origin: a patent overview

2020 ◽  
Vol 9 (3) ◽  
pp. 87-116
Author(s):  
Naseem Akhtar ◽  
Salman AA Mohammed ◽  
Varsha Singh ◽  
Ahmed AH Abdellatif ◽  
Hamdoon A Mohammad ◽  
...  
Keyword(s):  
Anticancer Agents ◽  
Chemotherapeutic Agents ◽  
World Intellectual Property Organization ◽  
European Patent ◽  
Sustained Delivery ◽  
The Us ◽  
Effective Delivery ◽  
Patent Literature ◽  
Delivery Options ◽  
Delivery Module

Phospholipid-based liposomal vesicles are among the most effective delivery options currently available for various classes of anticancer drugs. The patents granted to inventions disclosing details on liposomal delivery module by the US Patent and Trademark Office, European Patent Office, and world patent holdings through WIPO (World Intellectual Property Organization) patenting have been sorted based upon liposome, and anticancer keywords within the abstract and claims sections of the patents for the period between 2000 and 2019, thereby disclosing novel liposome formulations encapsulating single, or combination of chemotherapeutic agents that have been far more chemically and physiologically stable, therapeutically efficacious, and comparatively less toxic than their nonliposomal free-drug counterparts. The added stability, site-specific transport, and payload delivery, enhanced bioavailability, fast body clearance, and biocompatibility together with the controlled and sustained delivery-related benefits claimed in the patent literature have been exclusively discussed with a focus on the last 5-year period.

scholarly journals Microalgal protein AstaP is a potent carotenoid solubilizer and delivery module with a broad carotenoid binding repertoire

2021 ◽  
Author(s):  
Yury B Slonimskiy ◽  
Nikita A Egorkin ◽  
Thomas N. Friedrich ◽  
Eugene G. Maksimov ◽  
Nikolai N. Sluchanko
Keyword(s):  
Escherichia Coli ◽  
Neurodegenerative Disorders ◽  
Biomedical Applications ◽  
Protein Complexes ◽  
Water Soluble ◽  
Biological Functions ◽  
Cost Efficient ◽  
Delivery Module ◽  
Β Carotene

Carotenoids are lipophilic substances with many biological functions, from coloration to photoprotection. Being potent antioxidants, carotenoids have multiple biomedical applications, including the treatment of neurodegenerative disorders and retina degeneration. Nevertheless, the delivery of carotenoids is substantially limited by their poor solubility in the aqueous phase. Natural water-soluble carotenoproteins can facilitate this task, necessitating studies on their ability to uptake and deliver carotenoids. One such promising carotenoprotein, AstaP (Astaxanthin-binding protein), was recently identified in eukaryotic microalgae, but its structure and functional properties remained largely uncharacterized. By using a correctly folded recombinant protein, here we show that AstaP is an efficient carotenoid solubilizer that can stably bind not only astaxanthin but also zeaxanthin, canthaxanthin, and, to a lesser extent, β-carotene, i.e. carotenoids especially valuable to human health. AstaP accepts carotenoids provided as acetone solutions or embedded in membranes, forming carotenoid-protein complexes with an apparent stoichiometry of 1:1. We successfully produced AstaP holoproteins in specific carotenoid-producing strains of Escherichia coli, proving it is amenable to cost-efficient biotechnology processes. Regardless of the carotenoid type, AstaP remains monomeric in both apo- and holoforms, while its rather minimalistic mass (~20 kDa) makes it an especially attractive antioxidant delivery module. In vitro, AstaP transfers different carotenoids to the liposomes and to unrelated proteins from cyanobacteria, which can modulate their photoactivity and/or oligomerization. These findings expand the toolkit of the characterized carotenoid-binding proteins and outline the perspective of the use of AstaP as a unique monomeric antioxidant nanocarrier with an extensive carotenoid-binding repertoire.

Sign in / Sign up

Export Citation Format

Share Document